Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexis Talbot

Showing results (21-30 of 64) with videos related to

Pageof 7
Sort By:
Medicine|December 30, 2018
Multiple myeloma with crystal-storing histiocytosis, crystalline podocytopathy, and light chain proximal tubulopathy, revealed by retinal abnormalities: A case reportIdris Boudhabhay, Chérif Titah, Alexis Talbot, et al.
Leukemia|June 8, 2021
Correction to: The long non-coding RNA CRNDE regulates growth of multiple myeloma cells via an effect on IL6 signalingAntoine David, Simone Zocchi, Alexis Talbot, et al.
La Revue De Medecine Interne|August 8, 2024
[Serum hyperviscosity syndrome: Update 2024]Pierre-Edouard Debureaux, Nathalie Parquet, Anne C Brignier, et al.
Leukemia|September 4, 2020
The long non-coding RNA CRNDE regulates growth of multiple myeloma cells via an effect on IL6 signallingAntoine David, Simone Zocchi, Alexis Talbot, et al.
Haematologica|July 3, 2025
Teclistamab for heavily pretreated relapsed / refractory POEMS syndromeAlexis Talbot, Nathalie Forgeard, Tristan Vaugeois, et al.
Acta Dermato-Venereologica|March 16, 2021
Neutrophilic Urticaria with Systemic Inflammation Associated with Immunoglobulin A MyelomaHéloïse Paugoy, Anne Saussine, Laure Frumholtz, et al.
Immunotherapy|August 21, 2025
Gamma heavy chain disease treated with daratumumab-based regimen: a first case report and review of literatureCarla Cicerchia, Tristan Vaugeois, Nathalie Forgeard, et al.
Haematologica|July 18, 2020
Bi38-3 is a novel CD38/CD3 bispecific T-cell engager with low toxicity for the treatment of multiple myelomaMaxime Fayon, Carolina Martinez-Cingolani, Audrey Abecassis, et al.
Therapeutic Advances in Hematology|August 4, 2025
Safety of venetoclax in real-world experience: data from the French national database of pharmacovigilance through all indications in hematological malignancies over 5 yearsAlexis Talbot, Pierre-Edouard Debureaux, Agnès Lillo-Le Louet, et al.
British Journal of Haematology|December 17, 2019
Development of thrombotic thrombocytopenic purpura during lenalidomide therapy: three new cases and review of literatureDikélélé Elessa, Alexis Talbot, Naëlle Lombion, et al.
Pageof 7

Showing results (21-30 of 64) with videos related to

Sort By:
Pageof 7
Medicine|December 30, 2018
Multiple myeloma with crystal-storing histiocytosis, crystalline podocytopathy, and light chain proximal tubulopathy, revealed by retinal abnormalities: A case reportIdris Boudhabhay, Chérif Titah, Alexis Talbot, et al.
Leukemia|June 8, 2021
Correction to: The long non-coding RNA CRNDE regulates growth of multiple myeloma cells via an effect on IL6 signalingAntoine David, Simone Zocchi, Alexis Talbot, et al.
La Revue De Medecine Interne|August 8, 2024
[Serum hyperviscosity syndrome: Update 2024]Pierre-Edouard Debureaux, Nathalie Parquet, Anne C Brignier, et al.
Leukemia|September 4, 2020
The long non-coding RNA CRNDE regulates growth of multiple myeloma cells via an effect on IL6 signallingAntoine David, Simone Zocchi, Alexis Talbot, et al.
Haematologica|July 3, 2025
Teclistamab for heavily pretreated relapsed / refractory POEMS syndromeAlexis Talbot, Nathalie Forgeard, Tristan Vaugeois, et al.
Acta Dermato-Venereologica|March 16, 2021
Neutrophilic Urticaria with Systemic Inflammation Associated with Immunoglobulin A MyelomaHéloïse Paugoy, Anne Saussine, Laure Frumholtz, et al.
Immunotherapy|August 21, 2025
Gamma heavy chain disease treated with daratumumab-based regimen: a first case report and review of literatureCarla Cicerchia, Tristan Vaugeois, Nathalie Forgeard, et al.
Haematologica|July 18, 2020
Bi38-3 is a novel CD38/CD3 bispecific T-cell engager with low toxicity for the treatment of multiple myelomaMaxime Fayon, Carolina Martinez-Cingolani, Audrey Abecassis, et al.
Therapeutic Advances in Hematology|August 4, 2025
Safety of venetoclax in real-world experience: data from the French national database of pharmacovigilance through all indications in hematological malignancies over 5 yearsAlexis Talbot, Pierre-Edouard Debureaux, Agnès Lillo-Le Louet, et al.
British Journal of Haematology|December 17, 2019
Development of thrombotic thrombocytopenic purpura during lenalidomide therapy: three new cases and review of literatureDikélélé Elessa, Alexis Talbot, Naëlle Lombion, et al.
Pageof 7